Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

NCT03881488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumor
Metastatic Cancer
Non-small Cell Lung Cancer
Small Cell Lung Cancer
Mesothelioma
Melanoma
Head and Neck Cancer

Interventions

DRUG: CTX-471
DRUG: Pembrolizumab (KEYTRUDA®)

Sponsor

Compass Therapeutics

Collaborators

[object Object]
[object Object]